Back to Massachusetts

H2500 • 2025

An Act relative to increasing access to epinephrine

An Act relative to increasing access to epinephrine

Active

The official status still shows this bill as active or still awaiting another formal step.

Sponsor
Moakley, Thomas W.
Last action
2025-10-16
Official status
Accompanied a new draft, see H4607
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

An Act relative to increasing access to epinephrine

An Act relative to increasing access to epinephrine By Representative Moakley of Falmouth and Senator Cyr, a joint petition (accompanied by bill, House, No.

What This Bill Does

  • An Act relative to increasing access to epinephrine By Representative Moakley of Falmouth and Senator Cyr, a joint petition (accompanied by bill, House, No.
  • 2500) of Thomas W.
  • Moakley relative to increasing access to epinephrine.
  • Public Health.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2025-10-16 House

    Accompanied a new draft, see H4607

  2. 2025-09-11 House

    Reporting date extended to Thursday, October 9, 2025

  3. 2025-06-06 Joint

    Hearing scheduled for 06/11/2025 from 09:00 AM-01:00 PM in A-1

  4. 2025-02-27 House

    Referred to the committee on Public Health

  5. 2025-02-27 Senate

    Senate concurred

Official Summary Text

An Act relative to increasing access to epinephrine
By Representative Moakley of Falmouth and Senator Cyr, a joint petition (accompanied by bill, House, No. 2500) of Thomas W. Moakley relative to increasing access to epinephrine. Public Health.

Current Bill Text

Read the full stored bill text
×

Bill H.2500

SECTION 1. Chapter 111 of the General Laws is hereby amended by inserting after section 4O the following section:-

Section 4P. (a) As used in this section, the following words shall have the following meanings unless the context clearly requires otherwise:

"Authorized entity" means any entity or organization at which allergens capable of causing anaphylaxis may be present, including, but not limited to, restaurants, recreation camps, youth sports leagues, amusement parks, colleges, universities, and sports arenas.

"Epinephrine autoinjector" means a single-use device used for the automatic injection of a premeasured dose of epinephrine into the human body

(b) An authorized entity may acquire and maintain a supply of epinephrine autoinjectors from a wholesaler approved by the department pursuant to this section. All acquired epinephrine autoinjectors shall be stored in a location readily accessible in an emergency and in accordance with the epinephrine autoinjector's instructions for use. An authorized entity shall designate employees or agents who have completed the training required by subsection (d) of this section to be responsible for the storage, maintenance and general oversight of epinephrine autoinjectors acquired under this section.

(c) An employee or agent of an authorized entity who has completed the training required by subsection (d) of this section may, on the premises of or in connection with the authorized entity, use epinephrine autoinjectors obtained under this section to provide or administer an epinephrine autoinjector to any individual who the employee or agent believes in good faith is experiencing anaphylaxis for immediate self-administration, regardless of whether the individual has a prescription for an epinephrine autoinjector or has previously been diagnosed with an allergy.

(d) An employee, agent, or other individual described in subsection (c) of this section must complete an anaphylaxis training program prior to providing or administering an epinephrine autoinjector made available by an authorized entity. The training must be conducted by a nationally recognized organization experienced in training laypersons in emergency health treatment or by an entity or individual approved by the department of public health. The entity shall submit proof of training to the department and receive approval for the acquisition of epinephrine autoinjectors.

(e) An authorized entity that possesses and makes available epinephrine autoinjectors and its trained employees and agents shall not liable for any injuries or related damages that result from the administration or self-administration of an epinephrine autoinjector, the failure to administer an epinephrine autoinjector, or any other act or omission taken pursuant to this section, provided that said immunity does not apply to acts or omissions constituting gross negligence or willful or wanton misconduct.

(f) An authorized entity that possesses and makes available epinephrine autoinjectors shall submit to the department of public health, on a form developed by the department, a report of each incident on the authorized entity's premises that involves the distribution or administration of the authorized entity's epinephrine autoinjector. The department of public health shall annually publish a report that summarizes and analyzes all reports submitted to it under this subsection.

(g) The department shall promulgate guidance or regulations to carry out this section.

The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

Close